Risk factors of cyclosporine nephrotoxicity after conversion from Sandimmune to Neoral

Clinical Nephrology

Volumn 55, Issue 2, 2001, Pages 149-155

  Sijpkens, Y W J ^a   Mallat, M J K ^a   Siegert, C E H ^a   Zwinderman, A H ^a   Westendorp, R G J ^a   De Fijter, J W ^a   Van Es, L A ^a   Paul, L C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

blockers; Calcium channel blockers; Cyclosporine; Kidney transplantation; Neoral; Nephrotoxicity

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A;

ARTICLE; BLOOD PRESSURE; CREATININE BLOOD LEVEL; DOSE RESPONSE; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; CALCIUM CHANNEL BLOCKERS; CREATININE; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0035137745     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Renal function following conversion from Sandimmune to Neoral in stable renal transplant recipients
2. Long-term efficacy and safety of cyclosporine in renal transplant recipients
3. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: A report of the Canadian Neoral Renal Study Group
4. Neoral conversion from Sandimmune in maintenance renal transplant patients: An individualized approach
5. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: A preliminary report
6. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases
7. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients
8. Elective cyclosporine withdrawal 1 year after renal transplantation
9. Beneficial effects of conversion from cyclosporine to azathioprine after kidney transplantation
10. The impact of (1:1) cyclosporine A conversion to its microemulsion formulation on the kidney function of patients with cardiac allografts
11. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - A multicenter investigation in kidney transplant patients
12. Long-term maintenance of therapeutic cyclosporine levels leads to optimal graft survival without evidence of chronic nephrotoxicity
13. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: Its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation
14. Risk factors for the development of chronic cyclosporine-nephrotoxicity
15. The side-effects of cyclosporine A and tacrolimus
16. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy
17. Substitution of conventional cyclosporine with a new microemulsion formulation in renal transplant patients: Results after 1 year
18. Cyclosporine monitoring in patients with renal transplants: Two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure
19. Effect of nitrendipine on renal function in renal transplant patients treated with cyclosporine: A randomized trial
20. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation
21. Studies on the innervation of human renal allografts
22. Cyclosporine nephropathy: Pathophysiology and clinical impact
23. ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy